title: Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children.
abstract: We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.
authors.affiliation: Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
authors.forename: Ruth A
authors.initials: RA
authors.lastname: Karron
authors.affiliation: Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
authors.forename: Jocelyn
authors.initials: J
authors.lastname: San Mateo
authors.affiliation: Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
authors.forename: Bhagvanji
authors.initials: B
authors.lastname: Thumar
authors.affiliation: Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy, Immunology, and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
authors.forename: Anne
authors.initials: A
authors.lastname: Schaap-Nutt
authors.affiliation: Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy, Immunology, and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
authors.forename: Ursula J
authors.initials: UJ
authors.lastname: Buchholz
authors.affiliation: Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy, Immunology, and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
authors.forename: Alexander C
authors.initials: AC
authors.lastname: Schmidt
authors.affiliation: Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy, Immunology, and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
authors.forename: Emmalene J
authors.initials: EJ
authors.lastname: Bartlett
authors.affiliation: Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy, Immunology, and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
authors.forename: Brian R
authors.initials: BR
authors.lastname: Murphy
authors.affiliation: Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy, Immunology, and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
authors.forename: Peter L
authors.initials: PL
authors.lastname: Collins
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D002675:Child, Preschool; D004311:Double-Blind Method; D006801:Humans; D007223:Infant; D022241:Parainfluenza Vaccines / Q000627:therapeutic use*; D010222:Parainfluenza Virus 1, Human; D018184:Paramyxoviridae Infections / Q000453:epidemiology / Q000517:prevention & control*; D014613:Vaccines, Attenuated / Q000627:therapeutic use
chemical_list: D000914:Antibodies, Viral; D022241:Parainfluenza Vaccines; D014613:Vaccines, Attenuated
keywords: HPIV-1 vaccine; children; lower respiratory tract illness